Line Associated Thrombosis in Pediatric Patients With NF-κB Pathway Variants.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
03
11
2019
accepted:
09
01
2020
pubmed:
8
2
2020
medline:
20
5
2021
entrez:
8
2
2020
Statut:
ppublish
Résumé
Our report explores the complex role that nuclear factor-kappa B (NF-κB) plays in thrombosis formation, inflammation, and immunity; while additionally demonstrating that patients with NF-κB pathway pathogenic variants appear to carry a substantial thrombotic risk, particularly when secondary thrombotic risk factors are present. We propose that prophylactic anticoagulation should be strongly considered in such patients during high-risk situations and provide additional hematologic management strategies for those with NF-κB pathway alterations. We hope our work also calls to attention the potential need for a broader assessment of venous thromboembolism risk in patients with immune dysregulation to better delineate which patient populations may benefit from anticoagulation prophylaxis.
Identifiants
pubmed: 32032247
pii: 00043426-202104000-00036
doi: 10.1097/MPH.0000000000001739
doi:
Substances chimiques
Anticoagulants
0
Heparin, Low-Molecular-Weight
0
NF-kappa B
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e436-e437Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Branchford BR, Mourani P, Bajaj L, et al. Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. Haematologica. 2012;97:509–515.
Raffini L, Huang Y-S, Witmer C, et al. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124:1001–1008.
Scoville EA, Konijeti GG, Nguyen DD, et al. Venous Thromboembolism in Patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:631–636.
Blower K, Seifi A, Michalek J, et al. Incidence of VTE in patients with cystic fibrosis: are they high risk? CHEST. 2016;150:1135A.
Maubach G, Schmädicke A-C, Naumann M. NEMO links nuclear factor-κB to human diseases. Trends Mol Med. 2017;23:1138–1155.
Kawai T, Nishikomori R, Heike T. Diagnosis and treatment in anhidrotic ectodermal dysplasia with immunodeficiency. Allergol Int. 2012;61:207–217.
Mussbacher M, Salzmann M, Brostjan C, et al. Cell type-specific roles of NF-κB linking inflammation and thrombosis. Front Immunol. 2019;10:1–31.
Pathak R, Shao L, Chafekar SM, et al. IKKβ regulates endothelial thrombomodulin in a Klf2-dependent manner. J Thromb Haemost. 2014;12:1533–1544.
Kojok K, El-Kadiry AE-H, Merhi Y. Role of NF-κB in platelet function. Int J Mol Sci. 2019;20:4185.
Malaponte G, Signorelli SS, Bevelacqua V, et al. Increased levels of NF-kB-dependent markers in cancer-associated deep venous thrombosis. PLoS One. 2015;10:e0132496.
Kiriakidis S, Andreakos E, Monaco C, et al. VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase-defective form of the IκB kinase 2. J Cell Sci. 2003;116:665–674.
Hashikata T, Yamaoka-Tojo M, Namba S, et al. Rivaroxaban inhibits angiotensin II-induced activation in cultured mouse cardiac fibroblasts through the modulation of NF-κB pathway. Int Heart J. 2015;56:544–550.
Brandt KJ, Fickentscher C, Boehlen F, et al. NF-κB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes. J Thromb Haemost. 2014;12:779–791.
Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, et al. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost. 2002;88:851–857.
Evstatiev R. Iron deficiency, thrombocytosis and thromboembolism. Wien Med Wochenschr. 2016;166:437–446.